Literature DB >> 1728987

T-cell growth factors and the treatment of patients with cancer.

M T Lotze1.   

Abstract

T-cell maturation has traditionally been felt to occur primarily within the thymus but it is now clear that dynamic processes in the periphery govern many functions such as T-cell activation, proliferation, tolerization, and migration into peripheral tissues. Four T-cell growth factors have now been identified. These include: interleukin-2 (IL-2), IL-4, IL-7, and a potent cofactor recently described, IL-10. These factors are believed to work synergistically in the fine regulation of the lymphoid pool. Both IL-2 and IL-4 have entered clinical trials with significant responses in the IL-2-based regimens of up to 40 to 50% in certain tumors. IL-7 and IL-10 are in preclinical studies. Although IL-2, IL-4, and IL-7 have been shown to induce lymphokine-activated killer cell activity from sensitive precursors, such studies have yet to be performed with IL-10.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1728987     DOI: 10.1016/0090-1229(92)90040-u

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  2 in total

1.  Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake.

Authors:  Markus Loeffler; Jörg A Krüger; Andreas G Niethammer; Ralph A Reisfeld
Journal:  J Clin Invest       Date:  2006-06-22       Impact factor: 14.808

2.  Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression.

Authors:  F Nakajima; A Khanna; G Xu; M Lagman; R Haschemeyer; J Mouradian; J C Wang; K H Stenzel; A L Rubin; M Suthanthiran
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.